Key result
DOACs reduced the risk of stroke or systemic embolism by 16% compared to warfarin in patients with atrial fibrillation, an effect that remained consistent regardless of polypharmacy status.
Why the study?
It was unknown whether polypharmacy or drug-drug interactions differentially impact safety and efficacy in patients treated with DOACs versus warfarin.
Does DOAC therapy compared to warfarin improve clinical outcomes in patients with atrial fibrillation stratified by polypharmacy status?
Meta-Analysis (n=32,465)
Double-blind
Randomized
Yes
Does DOAC therapy compared to warfarin improve clinical outcomes in patients with atrial fibrillation stratified by polypharmacy status?
DOACs remain more effective and at least as safe as warfarin in patients with atrial fibrillation, regardless of polypharmacy status, though polypharmacy and interacting drugs may attenuate the bleeding advantage of rivaroxaban.
Answers are grounded in this paper and cite their sources.
Supports DOAC preference over warfarin in polypharmacy AF patients; confirms efficacy consistency across medication burden.
PURPOSE: To study whether polypharmacy or drug-drug interactions have differential effect on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus warfarin. METHODS: We performed a systematic review and meta-analysis of studies that randomized patients with atrial fibrillation to DOACs or warfarin stratified by the number of concomitant drugs. Outcomes included stroke or systemic embolism (SE), all-cause mortality, major bleeding, and intracranial hemorrhage. Risk ratios (RR) were calculated and Mantel-Haenszel random effects were applied. RESULTS: Two high-quality studies were eligible, including 32,465 participants who received apixaban, rivaroxaban, or warfarin, with a median follow-up of 1.9 years. Of participants, 29% used < 5 drugs, 55% used 5-9 drugs, and 16% used ≥ 10 drugs. Drugs interacting with DOACs (P-glycoprotein/CYP3A4) were used by 6460 (20%) of patients. Patients with higher number of drugs (0-4 vs 5-9 vs ≥ 10) had higher rates of mortality (5.8%, 7.9%, 10.0%) and major bleeding (3.4%, 4.8%, 7.7%). Comparative efficacy or safety of DOACs versus warfarin was not affected by polypharmacy status or P-glycoprotein/CYP3A4 inhibitor use. However, the presence of polypharmacy (p = 0.001) or glycoprotein/CYP3A4-modulating drugs (p = 0.03) was correlated with increased risk of major bleeding when compared with warfarin. Overall, DOAC use was associated with a lower risk of stroke/SE (RR, 0.84; 95%CI, 0.74-0.94), all-cause mortality (RR, 0.91; 95%CI, 0.84-0.98), and intracranial hemorrhage (RR, 0.51; 95%CI, 0.38-0.70) compared with warfarin. CONCLUSIONS: DOACs were more effective than warfarin, and at least as safe. Polypharmacy was associated with adverse outcomes and attenuated the advantage in risk of major bleeding among rivaroxaban users, particularly in the presence of P-glycoprotein/CYP3A4-modulating drugs.
No takes yet. Share an insight, caveat, or question.
Harskamp et al. (2019) conducted a meta-analysis in Atrial Fibrillation (n=32,465). DOACs (apixaban, rivaroxaban) vs. Warfarin was evaluated on Stroke or systemic embolism (RR 0.84, 95% CI 0.74-0.94). DOACs reduced the risk of stroke or systemic embolism by 16% compared to warfarin in patients with atrial fibrillation, an effect that remained consistent regardless of polypharmacy status.
Synapse has enriched 10 related papers. Consider them for comparative context: